普乐沙福在自体移植造血干细胞动员和单采中经济评估的系统综述数据集

数据集获取（Figshare）

• 源站标题：Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review
• DOI：10.6084/m9.figshare.21620983.v1
• 发布日期：2022-11-25
• 文件数：5 个
• 文件总体积：124.82 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_plerixafor_addition_in_the_mobilization_and_leukapheresis_of_hematopoietic_stem_cells_for_autologous_transplantation_a_systematic_review/21620983

命令行下载

curl -L -o "Supplementary Appendix A. Search strategies.docx" "https://ndownloader.figshare.com/files/38317237"
curl -L -o "Supplementary Appendix B. Full text studies excluded with reasons.docx" "https://ndownloader.figshare.com/files/38317240"
curl -L -o "Supplementary Appendix C. Outcomes and costs reported in each study used for ICER estimation.docx" "https://ndownloader.figshare.com/files/38317243"
curl -L -o "Supplementary Appendix D. Three-by-three dominance ranking matrix JBI.docx" "https://ndownloader.figshare.com/files/38317246"
curl -L -o "Supplementary Appendix E. Quality assessment of Kymes et al. 2012 with the Philips checklist.docx" "https://ndownloader.figshare.com/files/38317249"

文件清单

• Supplementary Appendix A. Search strategies.docx（15.79 KB）
• Supplementary Appendix B. Full text studies excluded with reasons.docx（30.70 KB）
• Supplementary Appendix C. Outcomes and costs reported in each study used for ICER estimation.docx（26.01 KB）
• Supplementary Appendix D. Three-by-three dominance ranking matrix JBI.docx（30.19 KB）
• Supplementary Appendix E. Quality assessment of Kymes et al. 2012 with the Philips checklist.docx（22.14 KB）

文件总体积 124.82 KB（源站 API 实测）。

数据说明

Although plerixafor in association with granulocyte colony-stimulating factor (G-CSF) can improve mobilization and collection of hematopoietic stem cells (HSC) by leukapheresis, cost may limit its clinical application. The present study systematically reviews economic evaluations of plerixafor plus G-CSF usage compared to G-CSF alone and compares different strategies of plerixafor utilization in multiple myeloma and lymphoma patients eligible for autologous HSC transplantation.
Relevant economic evaluations, partial or complete, were searched on PubMed, Embase, LILACS, and Cochrane Central Register of Controlled Trials for a period ending 30 June 2021. This systematic review was reported following the PRISMA Statement. Six economic evaluations were included, considering the use of upfront or just-in-time plerixafor compared to G-CSF alone or other plerixafor strategies. Most comparisons showed both increased cost and health benefits with the addition of plerixafor. Most analyses favored just-in-time plerixafor compared to upfront plerixafor, with a probable preference for broader cutoffs for just-in-time plerixafor initiation.
Plerixafor is a potentially cost-effective technology in the mobilization of HSC in patients with multiple myeloma and lymphomas eligible for autologous HSC transplantation. There is a decreased number of leukapheresis sessions and remobilizations and a higher yield of CD34+ cells.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.21620983.v1（source: https://tandf.figshare.com/articles/dataset/Economic_evaluation_of_plerixafor_addition_in_the_mobilization_and_leukapheresis_of_hematopoietic_stem_cells_for_autologous_transplantation_a_systematic_review/21620983）。